Allscripts trades at 18 times next year’s earnings and has a long-term growth rate of 24%. Cramer thinks the company should get a 25 multiple which would mean the stock should trade up to $17.50.

New Medicare rules will also provide reimbursements for in-home testing of sleep apnea. ResMed makes in-home testing and treatment equipment, so the company is in a great position to benefit as more people will be tested and need its products. Cramer said the stock could soar to $50 to $53 a share, but he cautioned investors to wait for a pullback after the shares ran up 7% today on takeover rumors.

Cramer said he prefers FMS because it has solid overseas exposure and its the best-of-breed stock in the sector. He also likes FMS for its growth into emerging markets like China, which is growing at 30% to 40%. The stock trades at 17 times earnings and sports a 11% long-term growth rate. Cramer thinks FMS can hit $65 and will earn $3.26 a share, vs. Wall Street estimates of $3.10 for 2009

Cramer told investors that dialysis plays Fesenius (FMS) and DaVita (DVA) are in a great position to benefit from this year’s Medicare spending bill. He pointed out that the current version of the bill provides dialysis companies with annual base-rate and inflation-rate payment increases. Cramer explained that FMS and DVA control 65% of the U.S. dialysis market.

Cramer said Pediatrix has already had its sell-off, with shares falling from a high of $70 a share to just $48 a share today. The company now trades at just 17 times its earnings with a long-term growth rate of 13%. Cramer gave the stock a target of $62 a share, or a 28% gain of today's levels.